MEDI4212
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MEDI4212, covering 2014-12-30 to 2014-12-30. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL [Phase 1]